Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a ...

Eli Lilly has suffered a major setback after the US regulator rejected its rheumatoid arthritis pill, baricitinib, sending the company’s share price plummeting. Lilly received a letter from the ...

I think Lilly will dominate this market over the long term despite competition, thanks to its late-stage pipeline. Though others are working on similar drugs in pill form (today's GLP-1 drugs and ...

The conference will hear about mid-stage studies of a Lilly pill that targets one hunger receptor ... for marketing to ...